| 764608 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
657 Characterization and therapeutic targeting of a tumor-associated tolerogenic DC subpopulation driven by SREBP2 and the mevalonate metabolic pathway |
2021-11-01 |
10.1136/jitc-2021-sitc2021.657 |
Plebanek Michael, DeVito Nicholas, Liu Fang, Theivanthiran Balamayooran, Beasley Georgia, Hanks Brent |
| 764607 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
654 Analysis of IDO-1 expression on dendritic cells and factors influencing its up- and downregulation in pancreatic cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.654 |
Hollingsworth Michael, Mehla Kamiya, Eberle Kirsten, Huang Ying, Triplett Aleata, Grandgenett Paul, Mundry Clara, Caffrey Thomas |
| 764606 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
652 Anti-PD-L1/IL-15 KD033 activated macrophages and induced anti-tumor immunity in the tumor-microenvironment |
2021-11-01 |
10.1136/jitc-2021-sitc2021.652 |
Martomo Stella, Wang George, Polonskaya Zhanna, Luna Xenia, Lu Dan, Patel Jeegar |
| 764605 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
651 Molecular signature of neoantigen-reactive CD4+ and CD8+ T cells from metastatic human cancers enables prospective antitumor TCR prediction |
2021-11-01 |
10.1136/jitc-2021-sitc2021.651 |
Lowery Frank, Krishna Sri, Yoseph Rami, Parikh Neilesh, Chatani Praveen, Lu Yong-Chen William, Zacharakis Nikolaos, Robbins Paul, Parkhurst Maria, Rosenberg Steven |
| 764604 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
471 Pharmacokinetics of first and repeated dosing of non-irAE-inducing anti-CTLA-4 monoclonal antibody ONC-392 in advanced cancer patients |
2021-11-01 |
10.1136/jitc-2021-sitc2021.471 |
Chou Hung-Yen, Li Tianhong, Kelly Karen, Martinez Anthony, Joo Stacy, Tang Mei, Devenport Martin, Liu Yang, Zheng Pan |
| 764603 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
470 A phase 1/2, open-label, dose escalation and expansion study of GI-101 as a single agent and in combination with a pembrolizumab, lenvatinib or local RT in advanced solid tumors (KEYNOTE-B59) |
2021-11-01 |
10.1136/jitc-2021-sitc2021.470 |
Cho Byoung Chul, Shin Sang Joon, Lee Jae-Lyun, Shim Byoung Yong, Park Hyung Soon, Yun Nari, Ham Mina, Koh Young Jun, Jang Myoung Ho |
| 764602 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
469 A phase 1 first in human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies |
2021-11-01 |
10.1136/jitc-2021-sitc2021.469 |
DiMascio Leah, Thakkar Dipti, Guan Siyu, Rowinsky Eric, Rodon Jordi, Gruber Joshua, Musher Benjamin, Kim Joseph, Mita Alain, Mita Monica, Ingram Piers, Boyd-Kirkup Jerome |
| 764601 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
466 Use of a 27-gene immuno-oncology (IO) assay to associate response to single-agent immune checkpoint inhibitor (ICI) therapy in advanced-stage NSCLC patients from a large Canadian cohort |
2021-11-01 |
10.1136/jitc-2021-sitc2021.466 |
Saltman David, Croteau Nicole, Lockyer Heather, Seitz Rob, McMahon Frank, Spille Jeremy, Dickey Andrea, Varga Matthew, McGregor Kim, Nielsen Tyler, Hout David, Schweitzer Brock, Ross Douglas, Gandara David |
| 764600 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
465 Bintrafusp alfa in combination with chemotherapy in patients with stage IV NSCLC: safety and pharmacokinetic results of the INTR@PID LUNG 024 study |
2021-11-01 |
10.1136/jitc-2021-sitc2021.465 |
Rolfo Christian, Greillier Laurent, Veillon Remi, Badin Firas, Ghiringhelli Francois, Isambert Nicolas, Paulus Astrid, Lambrechts Marc, Chaudhary Surendra, You Xiaoli, Vugmeyster Yulia, Helwig Christoph, Hiret Sandrine |
| 764599 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data |
2021-11-01 |
10.1136/jitc-2021-sitc2021.462 |
Jaderberg Magnus, Paz-Ares Luis, Cedres Susana, Ricordel Charles, Isambert Nicolas, Aix Santiago Ponce, Levitsky Victor, Kuryk Lukasz, Moller Anne-Sophie, Vetrhus Sylvia |
